Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Boston Scientific (BSX)
TipRanks (Fri, 21-Aug 9:30 AM ET)
PRNewswire (Mon, 10-Aug 8:00 AM ET)
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
PRNewswire (Thu, 30-Jul 4:05 PM ET)
Boston Scientific announces results for second quarter 2026
PRNewswire (Wed, 29-Jul 6:31 AM ET)
Boston Scientific’s $2 Billion Buyback Aims to Boost EPS and Shareholder Value Through 2026
Market Chameleon (Mon, 18-May 3:31 AM ET)
Market Chameleon (Wed, 22-Apr 7:56 AM ET)
Boston Scientific Delivers Robust Q1 Growth and Upgrades Guidance on Strong Segment Performances
Market Chameleon (Wed, 22-Apr 3:59 AM ET)
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Boston Scientific trades on the NYSE stock market under the symbol BSX.
As of August 21, 2026, BSX stock price climbed to $50.37 with 32,231,267 million shares trading.
BSX has a beta of 0.48, meaning it tends to be less sensitive to market movements. BSX has a correlation of 0.02 to the broad based SPY ETF.
BSX has a market cap of $74.86 billion. This is considered a Large Cap stock.
Last quarter Boston Scientific reported $5 billion in Revenue and $.86 earnings per share. This beat revenue expectation by $66 million and exceeded earnings estimates by $.03.
In the last 3 years, BSX traded as high as $109.50 and as low as $42.20.
The top ETF exchange traded funds that BSX belongs to (by Net Assets): VTI, VOO, IVV, SPY, XLV.
BSX has underperformed the market in the last year with a return of -52.5%, while the SPY ETF gained +21.2%. In the last 3 month period, BSX fell short of the market, returning -11.1%, while SPY returned +3.6%. However, in the most recent 2 weeks BSX has outperformed the stock market by returning +2.2%, while SPY returned -0.4%.
BSX support price is $48.18 and resistance is $50.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BSX shares will trade within this expected range on the day.